Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, published by SPRINGER, is a pivotal journal in the fields of cell biology and developmental biology, focusing on in vitro studies that enhance our understanding of animal cellular mechanisms and development. With an ISSN of 1071-2690 and an E-ISSN of 1543-706X, this esteemed journal offers a platform for researchers to present their findings and contribute to the body of knowledge necessary for advancements in biological sciences. As a recognized publication, it holds a 2023 category quartile of Q4 in Cell Biology and Developmental Biology, and Q3 in miscellaneous Medicine, reflecting its competitive position yet inviting critical submissions that can span multidisciplinary approaches. Though currently not open access, it serves as an essential resource for professionals, researchers, and students dedicated to unraveling the complexities of cellular processes in an ever-evolving field. The journal has been continuously published since 1986, signifying its long-standing commitment to fostering scientific discourse and innovation.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

Stem Cells Translational Medicine, published by Oxford University Press, is a leading open-access journal that has been at the forefront of stem cell research since its launch in 2012. With an impressive impact across various categories, it occupies Q2 in Cell Biology and is highly recognized in Q1 for both Developmental Biology and Miscellaneous Medicine in 2023. Its strong Scopus rankings highlight its significance in the fields of Biochemistry, Genetics, and Molecular Biology, achieving an outstanding percentile ranking of 93rd in Developmental Biology. The journal provides a pivotal platform for researchers, professionals, and students to publish and access cutting-edge findings that contribute to the understanding and application of stem cell technology. With a commitment to disseminating high-quality scientific knowledge, Stem Cells Translational Medicine plays a vital role in advancing research and innovation within the rapidly evolving landscape of regenerative medicine.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Stem Cell Research is a premier Open Access journal published by ELSEVIER, dedicated to advancing the understanding of stem cell biology. Since its inception in 2007, the journal has provided a platform for the latest research in the fields of Cell Biology, Developmental Biology, and Medicine, with its publication being accessible globally since 2014. Located in the Netherlands, the journal’s comprehensive scope aims to bridge fundamental discoveries with clinical applications, fostering collaboration among researchers and professionals. With a 2023 impact factor reflected in its Q4 ranking in Cell and Developmental Biology and a commendable position in the 64th percentile for General Medicine, Stem Cell Research remains a vital resource for those interested in the dynamic landscape of regenerative medicine. Targeting an audience that includes researchers, practitioners, and students, the journal emphasizes not only the significance of stem cells in medical science but also the ethical considerations and the public discourse surrounding stem cell research. Join the community committed to pioneering the future of stem cell science through rigorous peer-reviewed research.

Stem Cell Reviews and Reports is a prestigious journal published by SPRINGER specializing in the dynamic field of stem cell research, encompassing various aspects of cell biology and cancer research. With an ISSN of 2629-3269 and E-ISSN of 2629-3277, this journal serves as an essential resource for academics, offering insightful reviews and cutting-edge reports from 2009 to 2024. The journal has achieved a commendable Q2 ranking in both Cancer Research and Cell Biology categories as of 2023, highlighting its significant contribution to the scientific community. Additionally, with Scopus rankings placing it in the 74th percentile for both biochemistry and cell biology, it is recognized for its high-quality articles that foster innovative approaches in stem cell therapy and regenerative medicine. As an Open Access publication, Stem Cell Reviews and Reports ensures that its comprehensive content is readily available to researchers, professionals, and students, promoting collaboration and advancement in this vital area of study.

STEM CELLS AND DEVELOPMENT, published by Mary Ann Liebert, Inc., is a leading peer-reviewed journal dedicated to the rapidly advancing fields of stem cell biology and developmental science. With an ISSN of 1547-3287 and an E-ISSN of 1557-8534, the journal encompasses a broad range of topics central to understanding stem cells' roles in development and regeneration processes. It holds a prestigious standing within its category quartiles, ranking Q3 in Cell Biology, Q2 in Developmental Biology, and Q2 in Hematology for 2023. With its convergence from 2004 to 2024, STEM CELLS AND DEVELOPMENT fosters an innovative platform for researchers, professionals, and students to disseminate groundbreaking research, share insights, and explore novel therapeutic approaches. Open access options enhance the journal's visibility and accessibility, promoting a collaborative exchange of information among the scientific community. Positioned at the forefront of stem cell research and its applications, this journal is vital for anyone seeking to stay informed about the latest advancements and trends within these critical areas of study.

Stem Cells and Cloning-Advances and Applications is a leading peer-reviewed journal dedicated to the dynamic fields of stem cell research and cloning technologies. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this Open Access journal ensures that groundbreaking findings are accessible to a global audience. With a focus on innovative applications and advancements in cellular biology, the journal plays a pivotal role in disseminating knowledge within the scientific community. The journal currently holds an impact factor that reflects its influence, with notable rankings in both Cell Biology and Medicine (Miscellaneous), showcasing its interdisciplinary relevance. Researchers, professionals, and students alike benefit from the journal’s wide-ranging contributions, covering critical topics from regenerative medicine to genetic research. With a commitment to fostering collaboration and encouraging discussion in these cutting-edge domains, Stem Cells and Cloning-Advances and Applications continues to be a vital resource for advancing scientific inquiry and application.

Molecular Therapy Methods & Clinical Development, published by CELL PRESS, is a premier Open Access journal dedicated to advancing the field of gene and cell therapy through innovative methodologies and clinical developments. Since its inception in 2014, the journal has garnered significant attention within the research community, achieving impressive Q1 quartile rankings in Genetics, Molecular Biology, and Molecular Medicine as of 2023. With a commendable Scopus ranking that positions it within the top echelons of its categories, this journal serves as an essential platform for researchers, professionals, and students alike, providing access to cutting-edge research that drives the future of therapeutic approaches. With its commitment to Open Access, readers worldwide can easily access high-quality and impactful content that fosters collaboration and knowledge-sharing in this rapidly evolving domain. The journal’s scope encompasses crucial advancements in therapeutic methodologies, ensuring that it remains at the forefront of scientific discourse and innovation.